IL-12/IL-23p40 identified as a downstream target of apremilast in ex vivo models of arthritis.

Tue Wenzel KragstrupMary AdamsSøren LomholtMorten A NielsenLine D HeftdalPeter SchaferBent Deleuran

Published in: Therapeutic advances in musculoskeletal disease (2019)

This study reveals the downstream effects of apremilast in ex vivo models of arthritis with a strong inhibition of IL-12/IL-23p40 by SFMCs. Our findings could explain some of the efficacy of apremilast seen in IL-12/IL-23-driven immune-mediated inflammatory diseases such as psoriasis and PsA.

Keyphrases

prostate cancer
oxidative stress
radical prostatectomy